Mark Crotty
CEO & Managing Director
Industry Experience
• 25 years in healthcare (ANZ and Europe)
• Innovative & Generic, OTC & Medtech
• Significant experience in off patent management (Pfizer GM Established Products)
Biosimilars Experience
• Vice President Hospira (filgrastim and infliximab biosimilar)
• GBMA Chairperson (First contract with Federal govt; Biosimilars lobbying)
Anita Butko
National Key Account Manager
Industry Experience
• 15 years in healthcare – Schering Plough, Pierre Fabre, Amgen, Hospira, Pfizer
• Innovative & Generic, and Orthopaedic Surgical Devices
• Significant experience in Haem/Onc, Hospital Generics and Biosimilars
Biosimilars Experience
• Launched biosimilar filgrastim (Nivestim, 2011)
• Launched biosimilar infliximab (Inflectra, 2015)
• National KAM leading sales strategies for filgrastim and launch of Infliximab
• Biosimilar Pipeline projects
Mark Jaggers
Chief Commercial Officer
Industry Experience
• 20 years in healthcare (Australia, Asia and Europe) – Hexal, Sandoz, Hospira, Pfizer
• Retail & hospital generics, hospital specialty brands, biosimilars, & medical devices
Biosimilars Experience
• First biosimilar in Australia (Omnitrope, 2006)
• Global hospital biosimilar strategy roles
• MD driving growth in filgrastim, and launching infliximab
• GBMA biosimilars working group
Scott Voller
Director of Scientific Affairs
Industry Experience
• 25 years in Pharma (ANZ, APAC & Europe)
• 18 years of regulatory affairs
• Extensive experience in Hospital injectables (Faulding/Mayne/Hospira)
Biosimilars Experience
•European Regulatory Director overseeing registrations for biosimilar EPO & filgrastim in Europe
